A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

By Arnoletti J.   Frolov A.   Eloubeidi M.   Keene K.   Posey J.   Wood T.   Greeno Edward   Jhala N.   Varadarajulu S.   Russo S.   Christein J.   Oster R.   Buchsbaum D.   Vickers S.  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 891-897

Springer Publishing Company

Access to resources Recommend Favorite

Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

By Sartore-Bianchi Andrea  

Targeted Oncology, Vol. 5, Iss. 1, 2010-03 ,pp. : 19-28

Springer Publishing Company

Access to resources Recommend Favorite

Cyclooxygenase-2 (COX-2), Epidermal Growth Factor Receptor (EGFR), and Her-2/neu Expression in Ovarian Cancer

By Ferrandina G.   Ranelletti F.O.   Lauriola L.   Fanfani F.   Legge F.   Mottolese M.   Nicotra M.R.   Natali P.G.   Zakut V.H.   Scambia G.  

Gynecologic Oncology, Vol. 85, Iss. 2, 2002-05 ,pp. : 305-310

Academic Press

Access to resources Recommend Favorite

Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy

By  

Current Cancer Therapy Reviews, Vol. 3, Iss. 2, 2007-05 ,pp. : 117-126

Bentham Science Publishers

Access to resources Recommend Favorite

Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer

By Tsutsui S.  

Breast Cancer Research and Treatment, Vol. 71, Iss. 1, 2002-01 ,pp. : 67-75

Springer Publishing Company

Access to resources Recommend Favorite